Insulin Pump Failures: Has There Been an Improvement? Update of a Prospective Observational Study.

BACKGROUND Insulin pump failures had been assessed in our center by a prospective observational study from 2001 to 2007. The aim of this study was to update our data since 2008 and to determine whether there exist specific risk factors for insulin pump failures. METHODS All insulin pump defects were prospectively collected between 2008 and 2013 in a monocentric cohort of 350 new pumps. Clinical consequences were recorded. Brand and model of pumps and type of defects and patients' characteristics (gender, type of diabetes, age at diabetes diagnosis, age at first pump, pump treatment duration, number of previous pumps, and number of previous pump failures) were tested for possible association with insulin pump failure. RESULTS Malfunctions occurred in 239 (68%) pumps. The incidence rate was 33/100 pump-years. There were 28 (12%) complete failures, 17 (7%) alarms, 83 (35%) mechanical defects, and 105 (44%) minor defects. Survival curves did not differ according to pump brand and model. Hyperglycemia occurred in 2.9% of cases. In multivariate analysis, only patient age less than 40 years at the initiation of pump therapy was associated with higher risk of malfunction (hazard ratio 1.64; 95% confidence interval 1.19-2.24; P = 0.002). CONCLUSIONS Pump malfunctions remain common with modern pumps. We report less complete failures than in our previous study. This could be because of improvement in quality of pumps or to our strategy of systematic screening and replacement in case of mechanical defects.

[1]  M. Matsuhisa,et al.  Safety of the batteries and power units used in insulin pumps: A pilot cross‐sectional study by the Association for the Study of Innovative Diabetes Treatment in Japan , 2017, Journal of diabetes investigation.

[2]  T. Klupa,et al.  Europe has to step up its efforts to produce innovative and safe diabetes technology , 2017, Diabetologia.

[3]  R. Hovorka,et al.  Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics , 2015, Diabetes/metabolism research and reviews.

[4]  Gian Vincenzo Zuccotti,et al.  Impact of new technologies on diabetes care. , 2015, World journal of diabetes.

[5]  E. Wiltshire,et al.  Clinical review: insulin pump-associated adverse events in adults and children , 2015, Acta Diabetologica.

[6]  G. Alexander Fleming,et al.  Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group , 2015, Diabetologia.

[7]  J. WheelerBenjamin,et al.  Insulin Pump–Associated Adverse Events in Children and Adolescents—A Prospective Study , 2014 .

[8]  J. Pickup,et al.  Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. , 2014, Diabetes technology & therapeutics.

[9]  G. Ambler,et al.  Insulin pump-associated adverse events in children and adolescents--a prospective study. , 2014, Diabetes technology & therapeutics.

[10]  G. Zuccotti,et al.  Insulin Pump Therapy in Children with Type 1 Diabetes: The Dark Side of the Moon , 2013, Journal of diabetes science and technology.

[11]  Matthew Page,et al.  Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.

[12]  F. Bonnet,et al.  Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007 , 2009, Diabetologia.

[13]  I. Rabbone,et al.  Adolescent Use of Insulin and Patient-Controlled Analgesia Pump Technology: A 10-Year Food and Drug Administration Retrospective Study of Adverse Events , 2008, Pediatrics.

[14]  J. Cope,et al.  Adolescent Use of Insulin and Patient-Controlled Analgesia Pump Technology: A 10-Year Food and Drug Administration Retrospective Study of Adverse Events , 2008, Pediatrics.

[15]  I Guilhem,et al.  Technical risks with subcutaneous insulin infusion. , 2006, Diabetes & metabolism.

[16]  H Keen,et al.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. , 1978, British medical journal.